Thomas P. Schnettler - May 21, 2021 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Thomas P. Schnettler, by Joseph Driscol, as Attorney-in-Fact
Stock symbol
AKYA
Transactions as of
May 21, 2021
Transactions value $
$0
Form type
4
Date filed
5/25/2021, 09:55 PM
Next filing
Oct 14, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKYA Common Stock 2.81M May 21, 2021 Held by Piper Sandler Merchant Banking Fund II, L.P. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy Award $0 +16.9K $0.00 16.9K May 21, 2021 Common Stock 16.9K $21.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 PSC Capital Management II LLC is the general partner of Piper Sandler Merchant Banking Fund II, L.P. Piper Sandler Companies is the manager of PSC Capital Management II LLC. The reporting person is the Co-CEO of PSC Capital Management II LLC and disclaims beneficial ownership of the shares held by Piper Sandler Merchant Banking Fund II, L.P.
F2 Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) May 21, 2022, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.